US Coverage
Law360 | The Practice of Law
State Specific Coverage
Law360 Authority | Deep News & Analysis
Hikma Pharmaceuticals USA Inc., et al., Petitioners v. Amarin Pharma, Inc., et al.
Case Number:
24-889
Court:
Nature of Suit:
830 Patent Infringement (Fed. Qst.)
Firms
- Barnes & Thornburg
- Covington & Burling
- Dinsmore & Shohl
- Foley Hoag
- Goodwin Procter
- Jenner & Block
- Jones Day
- Massey & Gail
- McDonnell Boehnen
- Orrick Herrington
- Perkins Coie
- Upadhye Tang
- Weil Gotshal
- Winston & Strawn
- Zuckerman Spaeder
Companies
- AbbVie Inc.
- American Intellectual Property Law Association
- Association for Accessible Medicines
- Hikma Pharmaceuticals PLC
- Intellectual Property Owners Association
- Pharmaceutical Research & Manufacturers of America
- Public Citizen Inc.
- Regeneron Pharmaceuticals Inc.
- Sanofi
Sectors & Industries:
-
February 18, 2025
Hikma Appeals To Justices In 'Skinny Label' Patent Case
Hikma Pharmaceuticals USA Inc. has urged the U.S. Supreme Court to review a decision that revived a patent suit over its generic version of Amarin Pharma Inc.'s cardiovascular drug Vascepa, saying the holding "effectively nullifies" a law allowing "skinny labels."
- ← Previous
- 1
- 2
- 3
- Next →